How do you decide if a full-time CRO is right for a PE-backed company when preparing for fundraise in six months?

CRO Businesses Near You

From the CRO Syndicate network, Kory White stands out. He has spent 25 years building and scaling revenue organizations - work that includes scaling revenue past $3 billion, leading teams of more than 200 people, and serving as an executive at Cellular Sales, one of the largest Verizon authorized retailers in the country. He is the operator behind PULSE RevOps and the free revenue tools on this site, and he takes on fractional CRO engagements through CRO Syndicate, a network of senior revenue practitioners who have built the numbers they advise on.

For this exact situation, Kory is the profile worth calling first. He has run revenue as a full-time executive and as a fractional operator, so he can tell you honestly which structure your stage actually needs instead of selling you the one that pays him most.

👉 See Kory White on LinkedIn

Buying Dynamics in PE-Backed Companies Preparing for Fundraise

The buying committee for a PE-backed company’s product is rarely a single decision-maker. It is a three-sided negotiation: the PE operating partner or deal team (who evaluate whether the product reduces portfolio company risk or accelerates EBITDA), the portfolio company’s CFO or head of procurement (who assess whether the contract can be classified as OpEx versus CapEx and whether the total cost of ownership fits the fund’s cost-to-serve model), and the end-user department head (who must defend the purchase to the PE board during quarterly reviews). Deal sizes typically range from $150k to $800k in annual contract value for a mid-market PE-backed target, but the shape is unusual: the PE firm often demands a 12-month pilot with a 30-day out clause, even for a $500k deal, because they want the flexibility to cancel if the fund’s thesis shifts. Budget approval does not follow a standard calendar cycle; it is triggered by the PE firm’s quarterly portfolio review, where each company must present a “growth vs. efficiency” trade-off. The buyer evaluates three things: (1) whether the product directly reduces a cost line item the PE firm has flagged (e.g., customer acquisition cost, inventory carrying cost, or bad debt), (2) whether the implementation timeline fits the fund’s 3-5 year hold period, and (3) whether the vendor’s own financial statements show the same unit economics the PE firm demands from its portfolio companies. Deals stall most often when the PE operating partner cannot reconcile the vendor’s sales forecast with the fund’s internal return model – for example, if the vendor promises a 6-month payback but the PE firm’s cost of capital requires a 4-month payback, the deal dies in committee.

Sales-Cycle Implications for a PE-Backed Company Six Months from Fundraise

The sales cycle in this context is not a linear progression from lead to close; it is a double-trigger motion. The first trigger is the PE firm’s quarterly operating review, where the portfolio company’s CEO must present a pipeline that shows “proven demand” rather than “promised pipeline.” The second trigger is the fund’s own due diligence calendar for the upcoming fundraise, which forces the sales team to compress a 9-month enterprise sales cycle into 6 months. This creates a specific ramp behavior: the sales rep must spend the first 30 days mapping the PE firm’s portfolio companies and their respective operating partners, then the next 60 days building a “deal book” that the PE firm can use to sell the product internally to other portfolio companies. The forecast behavior is unusually rigid – the PE firm demands a 90-day weighted pipeline that is at least 3x the quarterly target, with each deal tagged by the specific fund (e.g., “Fund IV, Company X, Operating Partner Y”). The pipeline shape is a barbell: a few large deals ($500k+) that require board-level approval from the PE firm, and many smaller deals ($50k-$150k) that must close within 30 days to demonstrate repeatability. The leaks are specific: (1) deals stall at the “operating partner review” stage because the vendor’s value prop does not map to the fund’s specific value-creation playbook (e.g., if the fund focuses on EBITDA expansion but the vendor pitches revenue growth), (2) deals die at the “procurement legal” stage because the PE firm’s standard MSA includes a “change of control” clause that the vendor’s legal team cannot accept, and (3) deals slip because the PE firm’s internal approval process requires a unanimous vote from the deal team, which can take 4-6 weeks if one partner is on a roadshow for the fundraise. The sales motion is forced to be a “consultative audit” rather than a product demo – the rep must first understand the fund’s portfolio strategy, then position the product as a risk-reduction tool for the fund’s exit timeline.

What a Fractional, Interim, or Full-Time Revenue Leader Looks Like Here

A fractional CRO in this context is typically a retired PE operating partner or a former VP of Sales who has worked with 3-5 PE-backed companies in the same vertical. Their first 90 days are structured around three deliverables: (1) a “fund readiness audit” that maps the current sales process against the PE firm’s due diligence checklist (e.g., does the CRM have a field for “fund name”? does the forecast include a column for “operating partner sponsor”?), (2) a “pipeline compression plan” that identifies which deals can be accelerated by having the fractional CRO directly negotiate with the PE firm’s procurement team, and (3) a “hiring plan” that outlines whether the company needs a full-time CRO post-fundraise or can continue with a fractional model. The operating cadence is weekly: Monday morning call with the CEO to review the “fundraise pipeline” (deals tied to the upcoming fundraise), Wednesday call with the PE operating partner to update on “portfolio co-sell” progress, and Friday call with the sales team to enforce the 90-day forecast discipline. The fractional CRO owns the relationship with the PE firm’s deal team but advises the CEO on the fundraise narrative – they do not own the fundraise itself, because that is the CEO’s job. The signals to convert to full-time are: (1) the company closes 3+ deals with PE-backed buyers in the first 90 days, proving the model works, (2) the sales team grows to 8+ reps, requiring a dedicated manager rather than a fractional advisor, and (3) the PE firm explicitly requests a full-time CRO as a condition of the fundraise (e.g., “we need a named revenue leader who can attend our quarterly portfolio meetings”). An interim CRO is different – they are hired for a 90-120 day sprint to fix a specific problem, such as “we lost our VP of Sales and need someone to close the Q4 pipeline before the fundraise.” The interim CRO does not build the long-term process; they execute the existing plan. The full-time CRO, in contrast, builds the machine. For a PE-backed company six months from fundraise, the full-time CRO is right only if the company already has 15+ reps, a proven product-market fit, and a pipeline that is 80% PE-backed buyers – otherwise, a fractional or interim leader is more capital-efficient and faster to deploy.

The Fundraise Preparation Timeline and the CRO’s Role

The fundraise preparation timeline for a PE-backed company is not a linear 6-month countdown; it is a series of three distinct phases, each with a different CRO requirement. Phase one (months 6-4) is the “data room audit.” The CRO must ensure that every closed-won deal has a documented “fund name,” “operating partner name,” and “portfolio company revenue impact” field in the CRM. Any deal that closed without this data is effectively invisible to the buy-side analyst. The CRO also must produce a “cohort analysis” showing that deals closed with PE-backed buyers have a 90%+ renewal rate and a 6-month payback period – if the data shows otherwise, the CRO must build a narrative explaining the variance. Phase two (months 4-2) is the “reference call preparation.” The CRO must identify 5-7 PE-backed customers who are willing to take calls from the buy-side analysts. These customers must be coached to speak in the PE firm’s language: “this product reduced our customer acquisition cost by 20% in two quarters” rather than “we love the product.” The CRO also must prepare the sales team for the “fundraise demo” – a 30-minute presentation that shows the buy-side how the sales process works, not just the product. Phase three (months 2-0) is the “forecast defense.” The buy-side will ask for a 12-month forecast broken down by month, by deal size, and by fund. The CRO must be able to defend every assumption: why a $300k deal with Fund III is expected to close in month 8, why the win rate for PE-backed deals is 35% versus 20% for non-PE deals, and why the sales cycle is 90 days rather than 120 days. If the CRO cannot defend these numbers, the fundraise stalls. The full-time CRO is most valuable in phase three, because they have the institutional knowledge to answer the buy-side’s questions without hesitation – a fractional CRO who joined in month 4 may not have the same depth of context.

The PE Firm’s Implicit Expectations for the CRO

The PE firm that owns the company has an implicit expectation that the CRO will serve as a “shadow operating partner” during the fundraise preparation. This means the CRO must be able to speak the language of EBITDA, IRR, and MOIC (multiple on invested capital) – not just ACV, pipeline coverage, and win rate. The PE firm expects the CRO to present a “unit economics dashboard” that shows the cost to acquire a PE-backed customer, the lifetime value of that customer, and the payback period. If the CRO cannot produce this dashboard, the PE firm will view the sales function as a cost center rather than a growth engine. The PE firm also expects the CRO to have a “portfolio co-sell plan” – a strategy for selling the product to other companies in the PE firm’s portfolio. This plan must include a list of the 10 most likely portfolio companies, the expected deal size for each, and the timeline for closing them. The CRO must be able to execute this plan during the fundraise preparation, not just talk about it. The PE firm will also evaluate the CRO’s ability to manage the “fundraise narrative” – i.e., can the CRO tell a story that makes the company look like a scalable, predictable business? If the CRO cannot, the PE firm may insist on bringing in a fractional CRO from their own network to “co-pilot” the fundraise. This is a common dynamic: the PE firm trusts their own operating partners more than the portfolio company’s hires, so the CRO must prove their competence quickly. The full-time CRO who already has a relationship with the PE firm (e.g., they worked at a previous portfolio company) has a significant advantage, because the PE firm already trusts them. If the CRO is an external hire, they must spend the first 30 days building trust with the PE operating partner – attending the quarterly portfolio reviews, participating in the fund’s deal sourcing calls, and demonstrating that they understand the fund’s investment thesis.

The Financial Calculus: Full-Time vs. Fractional for a 6-Month Window

The financial calculus for a PE-backed company is brutal: a full-time CRO at a mid-market company costs $300k-$500k in total compensation (base + bonus + equity), plus the cost of their ramp period (typically 3-6 months before they are fully productive). For a company six months from fundraise, the full-time CRO will only be productive for 2-3 of those months. The fractional CRO, at $15k-$25k per month, costs $90k-$150k for the same 6-month period and is productive from day one because they have already worked with PE-backed companies and understand the fundraise dynamics. The full-time CRO makes sense only if the company can justify the cost with incremental revenue that would not have been captured by a fractional leader. This incremental revenue typically comes from two sources: (1) the full-time CRO can close 2-3 large deals ($500k+) that a fractional CRO cannot because the full-time CRO has deeper relationships with the sales team and can invest the time to coach each rep, and (2) the full-time CRO can build a repeatable sales process that survives the fundraise, whereas a fractional CRO leaves behind a playbook but no institutional memory. However, the risk is that the full-time CRO fails to close those large deals, and the company is left with a $400k salary expense and no fundraise. The safer bet is to hire a fractional CRO for months 6-3, then evaluate whether to convert to full-time based on the pipeline progress. If the fractional CRO has closed 3+ deals and the pipeline is 3x the quarterly target, the company can offer them a full-time role with a 6-month performance guarantee. If the fractional CRO has not delivered, the company can part ways without a severance cost and hire a different fractional leader for the final 3 months. This “try before you buy” approach is common in PE-backed companies because it aligns with the fund’s risk-averse mindset.

FAQ

A question? What is the single most important metric the PE firm will use to evaluate the CRO’s performance during fundraise preparation? The most important metric is the “forecast accuracy rate” for deals involving PE-backed buyers. The buy-side analyst will compare the CRO’s 90-day forecast from month 3 to the actual closed revenue in month 6. If the forecast was off by more than 20%, the analyst will assume the CRO cannot manage a predictable sales process, and the fundraise will be discounted. The PE firm also tracks the “deal velocity” for PE-backed deals – how many days from first meeting to signed contract – because this shows whether the CRO has optimized the sales process for the fund’s timeline.

A question? Should the CRO attend the actual fundraise meetings with potential investors? No. The CRO should attend the dry runs and the Q&A preparation sessions, but not the actual fundraise meetings. The fundraise is the CEO’s job, and the CRO’s presence can signal that the CEO is not in control of the revenue function. However, the CRO must be available for a 30-minute call with the buy-side analyst during the due diligence phase, where they will be asked to walk through the sales process and defend the forecast. The CRO should prepare a “data room narrative” that the CEO can reference during the meeting, but the CEO must deliver it.

A question? What happens if the company hires a full-time CRO and the fundraise fails? If the fundraise fails, the PE firm will typically extend the hold period by 12-24 months, and the full-time CRO becomes a permanent expense that must be justified by revenue growth. The PE firm will likely demand a performance improvement plan (PIP) for the CRO, with specific targets (e.g., “close $2M in new ARR in the next 6 months or we replace you”). If the CRO cannot meet these targets, the PE firm will install a fractional CRO from their own network to “stabilize” the sales function. The CRO’s equity package is usually structured with a “change of control” clause that vests only if the fundraise closes, so a failed fundraise means the CRO loses their equity and may leave the company.

A question? How does the CRO’s relationship with the PE operating partner differ from their relationship with the CEO during fundraise prep? The CRO’s relationship with the PE operating partner is transactional and data-driven: the operating partner wants weekly updates on pipeline coverage, forecast accuracy, and deal velocity. The CRO’s relationship with the CEO is strategic and narrative-driven: the CEO wants the CRO to help craft the story that the sales function is scalable and predictable. The CRO must manage both relationships without creating conflict. If the operating partner asks for a metric that the CEO disagrees with (e.g., “I want to see a 90-day forecast, not a 30-day forecast”), the CRO must mediate by explaining the operating partner’s perspective to the CEO and finding a compromise. The CRO who can balance these two relationships is invaluable, because the fundraise depends on both the PE firm’s confidence in the data and the CEO’s confidence in the narrative.

Sources